Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findin...
2019年7月31日 - 10:00PM
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases, today announced that Daniel P. Lundberg,
Founder and former Chief Marketing Officer at Vivelix
Pharmaceuticals and former Senior VP of Marketing at Salix
Pharmaceuticals, will join Ritter Pharmaceuticals’ CEO, Andrew J.
Ritter, to present new insights and market research on the lactose
intolerance (LI) market.
The conference call will be held on August 7,
2019 at 1:30 PM ET/10:30 AM PT. Participants may register at any
time to gain access, including up to and after the call start time.
To register, go to: http://dpregister.com/10134115
The presentation and discussion will include:
- Projected market size of LI and target market for RP-G28
- Challenges LI patients face and the unmet medical need
- Physicians’ perspectives and insights on the disease and need
for new therapies
- Available channels for RP-G28 to activate the target
market
“This market research shines light on the needs
and behaviors of LI patients in search of new and innovative
therapeutics, especially, the moderate-to-severe population,” said
Mr. Lundberg. “By understanding and targeting key patient segments
that are most affected with LI symptoms, from both a physical and a
quality of life perspective, RP-G28 can deliver the greatest impact
on patient health and do so in an efficient manner.”
“We have a unique opportunity with RP-G28, which
has the potential to become the first FDA-approved drug of its kind
to effectively treat LI. In-depth market research has demonstrated
that LI sufferers are seeking a better option, and Ritter
Pharmaceuticals wants to provide them with a solution where they
don’t have to compromise between managing undesirable symptoms of
LI and avoiding dairy products altogether,” said Mr. Ritter.
In July 2019, the Company announced the
completion of “last patient last visit” in its Phase 3 trial of
RP-G28 for the potential treatment of LI, a study known as
“Liberatus.” Ritter Pharmaceuticals is on track to announce topline
results of the Liberatus trial in early Q4 2019.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.ritterpharma.com, @RitterPharma) develops innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases. The Company’s lead product candidate,
RP-G28, has the potential to become the first FDA-approved
treatment for lactose intolerance, a condition that affects
millions worldwide. RP-G28 is in Phase 3 clinical development with
its first Phase 3 clinical trial, known as “Liberatus,” currently
in its finalization stage with top-line data expected in early Q4
2019. The Company is further exploring the therapeutic potential
that gut microbiome changes may have on treating/preventing a
variety of diseases including: gastrointestinal diseases, cancer,
metabolic, and liver disease.
About Daniel P. Lundberg
Dan Lundberg is the Founder and President of
Pharmtegrity Consulting Services LLC, a consulting firm focused on
serving the pharmaceutical, biotechnology, and device industries.
Mr. Lundberg brings over 25 years of experience in sales, domestic
and international product management, business development,
marketing, commercial operations and executive-level leadership. He
is a Founder of and the former Chief Marketing Officer at Vivelix
Pharmaceuticals and former Senior VP of Marketing at Salix
Pharmaceuticals.
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that express the current beliefs and
expectations of Ritter Pharmaceuticals’ management. Any statements
contained herein that do not describe historical facts, including
statements related to our anticipated timing for the release of
data from our Liberatus clinical trial, are forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from those discussed in such
forward-looking statements. Some of the factors that could affect
our actual results are included in the periodic reports on Form
10-K and Form 10-Q that we file with the Securities and Exchange
Commission. Ritter cautions readers not to place undue reliance on
any forward-looking statements, which speak only as of the date
they were made. The Company undertakes no obligation to update or
revise forward-looking statements, except as otherwise required by
law, whether as a result of new information, future events or
otherwise.
ContactsInvestor Contact: Aida Attar
310-203-1000 Aida@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024